Opdivo success in phase III ATTRACTION-3 study to treat oesophageal cancer. BMS + Ono
Ono Pharmaceutical Co. Ltd.announced that Opdivo (nivolumab) met the primary endpoint vs. chemotherapy of improving overall survival in the Phase III ATTRACTION-3 trial to treat esophageal cancer. Opdivo is the first checkpoint inhibitor to significantly extend OS in patients with PD-L1 unselected, unresectable advanced or recurrent esophageal cancer.
The company, which did not report detailed data, plans to present additional data at a scientific meeting. The open-label, international trial enrolled about 390 patients refractory to or intolerant of one prior combination therapy with fluoropyrimidine and platinum-based therapy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.